Overview
Cryoport Q2 2025 revenue grows 14% yr/yr, beating analyst expectations
Life Sciences Services revenue rises 21%, driven by cell & gene therapy demand
Outlook
Cryoport reaffirms 2025 revenue guidance of $165 mln to $172 mln
Company expects 20 more application filings in 2025
Cryoport anticipates one new therapy approval in 2025
Result Drivers
CELL & GENE THERAPY DEMAND - Revenue from commercial cell & gene therapies increased 33% yr/yr, driven by growing adoption
BIOLOGISTICS SOLUTIONS - Revenue from BioLogistics Solutions rose 20% yr/yr, reflecting strong demand for integrated platform
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $45.50 mln | $41.70 mln (9 Analysts) |
Q2 Gross Margin | 47.0% |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the courier, postal, air freight & land-based logistics peer group is "buy"
Wall Street's median 12-month price target for Cryoport Inc is $10.50, about 31.8% above its August 4 closing price of $7.16
Press Release: ID:nPn9QvxxVa
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.